CLLS
CLLS clinical trials: Cellectis S.A.
Every trial on ClinicalTrials.gov where Cellectis S.A. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 6
- Trials linked
- 6
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
CLLS on the catalyst calendar · CLLS registry changes
- Primary completion Sep 16, 2026ActualPhase 1/Phase 2NCT04150497Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)Cellectis S.A. · B-cell Acute Lymphoblastic LeukemiaActive, not recruitingCLLSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2027Sponsor estimatePhase 1/Phase 2NCT05607420Study Evaluating UCART20x22 in B-Cell Non-Hodgkin LymphomaCellectis S.A. · B-cell Non-Hodgkin Lymphoma (B-NHL)RecruitingCLLSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 24, 2024ActualPhase 1NCT03190278Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaCellectis S.A. · Relapsed/Refractory Acute Myeloid LeukemiaActive, not recruitingCLLSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 18, 2023ActualPhase 1NCT04142619Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)Cellectis S.A. · Relapsed/Refractory Multiple MyelomaTerminatedCLLSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 5, 2019ActualPhase 1NCT04106076Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid LeukemiaCellectis S.A. · Acute Myeloid LeukaemiaWithdrawnCLLSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 27, 2019ActualPhase 1NCT03203369Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCNCellectis S.A. · Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)TerminatedCLLSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 6 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner